Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb 11;13(1):57-63.
doi: 10.1159/000519275. eCollection 2022 Jan-Apr.

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Saagar N Patel  1 , Mona L Camacci  1 , Esther M Bowie  1
Affiliations
Case Reports

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Saagar N Patel et al. Case Rep Ophthalmol. .

Abstract

We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days of metamorphopsia was found to have pseudovitelliform lesions in both eyes 6 weeks after initiation of erdafitinib. After discontinuation of this drug, his visual complaints resolved and his lesions decreased on optical coherence tomography. To our knowledge, this is the first case depicting reversible macular lesions with use of this newly approved medication outside of clinical trial protocols.

Keywords: Fibroblast growth factor receptor; Fibroblast growth factor receptor retinopathy; Mitogen-activated protein kinase; Mitogen-activated protein kinase kinase associated retinopathy; Optical coherence tomography.

PubMed Disclaimer

Conflict of interest statement

None of the authors have any financial disclosures or conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Fundus near-infrared reflectance of the right (a) and left (b) eye demonstrating a central hypo-reflective lesion with rim of hyper-reflectivity.
Fig. 2
Fig. 2
Optical coherence tomography images of right (a) and left (b) eye demonstrating hyper-reflective, subretinal material with trace subretinal fluid and without choroidal thickening (229 μm in both eyes).
Fig. 3
Fig. 3
Fundus near-infrared reflectance of the right (a) and left (b) eye demonstrating foci of hyper-reflectivity in area of previously central hypo-reflective lesion.
Fig. 4
Fig. 4
Optical coherence tomography images of right (a) and left (b) eye demonstrating decrease of previous hyper-reflective, subretinal material, and resolution of subretinal fluid. Choroidal thickness remained constant at 229 μm in both eyes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Loriot Y, Nechhi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381:338–348. - PubMed
    1. van der Noll R, Leijen S, Neuteboom GH, Beijnen JH, Schellens JH. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev. 2013;39((6)):664–672. - PubMed
    1. Catalani E, Tomassini S, Dal Monte M, Bosco L, Casini G. Localization patterns of fibroblast growth factor 1 and its receptors FGFR1 and FGFR2 in postnatal mouse retina. Cell Tissue Res. 2009;336:423–438. - PubMed
    1. Duncan KE, Chang LY, Patronas M. MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. Eye. 2015;29((8)):1003–1012. - PMC - PubMed
    1. McCannel TA, Chmeilowski B, Finn RS, Goldman J, Ribas A, Wainberg ZA, et al. Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer. JAMA Ophthalmol. 2014;132:1005–1009. - PubMed

Publication types